Skip to main content
Top
Published in: Familial Cancer 3/2010

01-09-2010

Familial adenomatous polyposis (FAP) and gender. Does gender influence the genetic transmission of FAP?

Authors: Eriberto Farinella, Ramawad Soobrah, Robin K. S. Phillips, Susan K. Clark

Published in: Familial Cancer | Issue 3/2010

Login to get access

Abstract

Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome with a penetrance close to 100% at the age of 40 years. The incidence is thought to be equal among both sexes, but we noticed an excess of males undergoing primary surgery for FAP at our institution. The aim of the study is to investigate the hypothesis that FAP patients produce an excess of affected male offspring. We identified all families with known APC mutation in the polyposis registry at St Mark’s from its foundation until October 2009. We analysed their pedigrees with respect to gender of the affected individuals with progeny and to the gender and mutation status of their offspring. Only individuals with complete data regarding their offspring (gender and mutation status) were included. We identified 666 (324 males and 342 females) affected individuals with progeny. We analysed the progeny of 368 (182 males, 186 females) affected individuals with complete data on all offspring: 235 (27.5%) affected males, 212 (24.8%) affected females, 207 (24.3%) unaffected males and 200 (23.4%) unaffected females. The overall ratio of affected/unaffected and male/female offspring did not differ from the expected 50%. Further sub-analysis by gender of parents did not show any statistically significant difference in gender and mutation status of offspring. In addition the mean number of children per affected parent did not depend on gender (males 2.34; females 2.30). This study shows that gender does not influence the genetic transmission of FAP. The excess of males undergoing primary surgery at our institution is probably a result of referral bias.
Literature
1.
go back to reference Cruz-Correa M, Giardiello FM (2003) Familial adenomatous polyposis. Gastrointest Endosc 58(6):885–894CrossRefPubMed Cruz-Correa M, Giardiello FM (2003) Familial adenomatous polyposis. Gastrointest Endosc 58(6):885–894CrossRefPubMed
2.
go back to reference Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3(2):121–125CrossRefPubMed Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3(2):121–125CrossRefPubMed
3.
go back to reference Bülow S (2003) Results of national registration of familial adenomatous polyposis. Gut 52(5):742–746CrossRefPubMed Bülow S (2003) Results of national registration of familial adenomatous polyposis. Gut 52(5):742–746CrossRefPubMed
4.
go back to reference Aretz S, Uhlhaas S, Caspari R, Mangold E, Pagenstecher C, Propping P, Friedl W (2004) Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet 12(1):52–58CrossRefPubMed Aretz S, Uhlhaas S, Caspari R, Mangold E, Pagenstecher C, Propping P, Friedl W (2004) Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet 12(1):52–58CrossRefPubMed
Metadata
Title
Familial adenomatous polyposis (FAP) and gender. Does gender influence the genetic transmission of FAP?
Authors
Eriberto Farinella
Ramawad Soobrah
Robin K. S. Phillips
Susan K. Clark
Publication date
01-09-2010
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2010
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9341-x

Other articles of this Issue 3/2010

Familial Cancer 3/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine